Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (661-670 of 962) with videos related to

Pageof 97
Sort By:
Journal of Cardiac Failure|March 2, 2026
Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients with Diabetes and Heart Failure: A SOLOIST-WHF Ancillary StudyAnis Ismail, Grace Erne, Alexi Vasbinder, et al.
European Heart Journal. Acute Cardiovascular Care|August 4, 2016
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experienceSergio Leonardi, Renato D Lopes, Ph Gabriel Steg, et al.
American Heart Journal|September 25, 2004
Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)Carlo Di Mario, Leonardo Bolognese, Luc Maillard, et al.
Circulation. Heart Failure|May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
European Heart Journal|August 22, 2020
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trialJosé Tuñón, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Cardiovascular Diabetology|October 17, 2020
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trialChao Gao, Mariusz Tomaniak, Kuniaki Takahashi, et al.
JAMA Cardiology|March 30, 2017
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical TrialPatricia A Cowper, Shubin Sheng, Renato D Lopes, et al.
Stroke|November 20, 2010
Prevalence of coronary atherosclerosis in patients with cerebral infarctionPierre Amarenco, Philippa C Lavallée, Julien Labreuche, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 17, 2021
External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trialMasafumi Ono, Hideyuki Kawashima, Hironori Hara, et al.
Journal of the American Heart Association|February 9, 2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial InfarctionGiulia Magnani, Diego Ardissino, KyungAh Im, et al.
Pageof 97

Showing results (661-670 of 962) with videos related to

Sort By:
Pageof 97
Journal of Cardiac Failure|March 2, 2026
Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients with Diabetes and Heart Failure: A SOLOIST-WHF Ancillary StudyAnis Ismail, Grace Erne, Alexi Vasbinder, et al.
European Heart Journal. Acute Cardiovascular Care|August 4, 2016
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experienceSergio Leonardi, Renato D Lopes, Ph Gabriel Steg, et al.
American Heart Journal|September 25, 2004
Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI)Carlo Di Mario, Leonardo Bolognese, Luc Maillard, et al.
Circulation. Heart Failure|May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
European Heart Journal|August 22, 2020
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trialJosé Tuñón, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Cardiovascular Diabetology|October 17, 2020
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trialChao Gao, Mariusz Tomaniak, Kuniaki Takahashi, et al.
JAMA Cardiology|March 30, 2017
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical TrialPatricia A Cowper, Shubin Sheng, Renato D Lopes, et al.
Stroke|November 20, 2010
Prevalence of coronary atherosclerosis in patients with cerebral infarctionPierre Amarenco, Philippa C Lavallée, Julien Labreuche, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 17, 2021
External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trialMasafumi Ono, Hideyuki Kawashima, Hironori Hara, et al.
Journal of the American Heart Association|February 9, 2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial InfarctionGiulia Magnani, Diego Ardissino, KyungAh Im, et al.
Pageof 97